TechnoPhage
Technophage is a clinical-stage biopharmaceutical company focused on discovery, development and GMP manufacture of biologics addressing infection, neurosciences and ophthalmology. The company develops bacteriophage-based therapeutics, recombinant single-domain antibodies and other biologic candidates, operates a GMP-certified manufacturing facility for investigational medicines, runs clinical trials (Phase I/IIa to Phase 2/2b) and participates in national R&D consortia for biopharmaceutical development and production.
Industries
Nr. of Employees
small (1-50)
TechnoPhage
Avenida Prof. Egas Moniz, Edifício Egas Moniz, Piso 2 – Ala A, 1649-028 Lisboa, Portugal
Patents
Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
US-11672839-B2
View DetailsAntibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
US-10654917-B2
View DetailsCompositions for use in treating parkinson's disease and related disorders
US-10471025-B2
View DetailsCompositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
US-9962419-B2
View Details
Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
US-11672839-B2
View DetailsAntibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
US-10654917-B2
View DetailsCompositions for use in treating parkinson's disease and related disorders
US-10471025-B2
View DetailsCompositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
US-9962419-B2
View DetailsProducts
TP-102 (bacteriophage cocktail)
A bacteriophage cocktail developed as a topical treatment for infected diabetic foot ulcers caused by pathogens including Pseudomonas aeruginosa, Staphylococcus aureus and Acinetobacter baumannii; progressed through Phase I/IIa and Phase 2b clinical studies and has received regulatory designations (e.g., FDA Fast Track).
TP-122 (bacteriophage therapeutic candidate)
A bacteriophage-based therapeutic candidate developed for treatment of pneumonia caused by Pseudomonas aeruginosa; progressed to regulatory approval to start a Phase 1/2a clinical study in Europe.
TZ-161 (therapeutic candidate for spinal cord injury)
A clinical-stage candidate being evaluated for treatment of acute spinal cord injury (Phase 1b/2a initiated).
TA-111 (biomarker product)
A biomarker product listed in the non-therapeutic pipeline (preclinical/clinical stages indicated).
C1/PD-0010 (dietary supplement)
A dietary supplement listed in the non-therapeutic pipeline.
TP-102 (bacteriophage cocktail)
A bacteriophage cocktail developed as a topical treatment for infected diabetic foot ulcers caused by pathogens including Pseudomonas aeruginosa, Staphylococcus aureus and Acinetobacter baumannii; progressed through Phase I/IIa and Phase 2b clinical studies and has received regulatory designations (e.g., FDA Fast Track).
TP-122 (bacteriophage therapeutic candidate)
A bacteriophage-based therapeutic candidate developed for treatment of pneumonia caused by Pseudomonas aeruginosa; progressed to regulatory approval to start a Phase 1/2a clinical study in Europe.
TZ-161 (therapeutic candidate for spinal cord injury)
A clinical-stage candidate being evaluated for treatment of acute spinal cord injury (Phase 1b/2a initiated).
TA-111 (biomarker product)
A biomarker product listed in the non-therapeutic pipeline (preclinical/clinical stages indicated).
C1/PD-0010 (dietary supplement)
A dietary supplement listed in the non-therapeutic pipeline.
Services
GMP production of biological medicines (investigational medicinal products), formulation and process development, and contract manufacturing inquiries.
Support for discovery, preclinical evaluation, clinical trial design and execution, investigator engagement and clinical operations for early- and mid-stage trials.
Discovery services using bacteriophage platforms, recombinant antibody platforms and biomarker development to generate therapeutic and non-therapeutic candidates.
Case-by-case evaluation and provision of pre-approval access to investigational drugs for eligible patients under regulatory and ethical requirements.
GMP production of biological medicines (investigational medicinal products), formulation and process development, and contract manufacturing inquiries.
Support for discovery, preclinical evaluation, clinical trial design and execution, investigator engagement and clinical operations for early- and mid-stage trials.
Discovery services using bacteriophage platforms, recombinant antibody platforms and biomarker development to generate therapeutic and non-therapeutic candidates.
Case-by-case evaluation and provision of pre-approval access to investigational drugs for eligible patients under regulatory and ethical requirements.
Expertise Areas
- Clinical trial management
- GMP biomanufacturing for investigational medicines
- Bacteriophage therapeutics development
- Biologics discovery and formulation (single-domain antibodies)
Key Technologies
- Bacteriophage therapy (phage cocktails)
- Recombinant single-domain antibodies
- GMP-compliant biologics manufacturing
- Formulation and process development for biologics
News & Updates
Participation in the REVERSE 2 / TP-102_102 Investigator Meeting to advance TP-102 development and foster collaboration with clinical partners.
Announcement that the Phase 1/2a clinical study TP-122_101A received regulatory approvals to proceed in Portugal and the Netherlands.
End of study for the TP-102 Phase 2b trial, representing a clinical development milestone for the product.
Announcement that the U.S. FDA cleared an IND application for a bacteriophage cocktail (TP-102) enabling initiation of a Phase I/IIa clinical trial.
Company was granted the COTEC Innovative Status for 2026 by COTEC Portugal.
Company was awarded the 'PME Excelência 2024' status recognizing financial performance and sustainable growth.
Participation in the REVERSE 2 / TP-102_102 Investigator Meeting to advance TP-102 development and foster collaboration with clinical partners.
Announcement that the Phase 1/2a clinical study TP-122_101A received regulatory approvals to proceed in Portugal and the Netherlands.
End of study for the TP-102 Phase 2b trial, representing a clinical development milestone for the product.
Announcement that the U.S. FDA cleared an IND application for a bacteriophage cocktail (TP-102) enabling initiation of a Phase I/IIa clinical trial.
Company was granted the COTEC Innovative Status for 2026 by COTEC Portugal.
Company was awarded the 'PME Excelência 2024' status recognizing financial performance and sustainable growth.